Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923376 | 0.89 | EPHX2 (0.49) | ALDH1A1LMNAKDM4E | |
| SCHEMBL5923306 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAKDM4ERAB9AHPGD | |
| SCHEMBL6925014 | 0.81 | TAAR1 (0.44) | ALDH1A1LMNAKDM4ETAAR1RAB9A | |
| SCHEMBL5923119 | 0.81 | HTT (0.48) | ALDH1A1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL6828231 | 0.81 | NMT1 (0.40) | ALDH1A1LMNAKDM4ETAAR1 | |
| SCHEMBL5923585 | 0.79 | AOC3 (0.46) | ALDH1A1LMNARAB9AMEN1KMT2A | |
| SCHEMBL5923052 | 0.78 | VCP (0.46) | ALDH1A1LMNAKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL13498020 | 0.76 | RAB9A (0.62) | ALDH1A1LMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6182664 | 0.76 | RAB9A (0.46) | ALDH1A1LMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5923123 | 0.76 | RAB9A (0.51) | ALDH1A1LMNAKDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| WO-2004037166-A2 | THERAPEUTIC GUANIDINES | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | ALDH1A1 1066/4885LMNA 3254/4885KDM4E 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.